- Details
- Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...
|
- Details
- Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...
|
- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zach Klaassen interviews Constantinos Zamboglou about a study on PSMA-PET/CT-guided salvage radiotherapy for recurrent prostate cancer after surgery. Dr. Zamboglou presents findings from a comparative analysis of PSMA-PET-guided and non-PSMA-guided salvage radiotherapy, using data from the SAKK09/10 trial and a retrospective database. The study demonstrates improved short- and mid-term biochemical...
|
- Details
- Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...
|
- Details
- In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...
|
- Details
- A Step Towards Personalized Medicine: PSMA-PET Imaging in Prostate Cancer F-18 DCFPyL PSMA Imaging for Prostate Cancer: OSPREY and CONDOR. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourinary Medical Oncology Service & Prostate Cancer Section...
|
- Details
- A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. The Biology of Prostate Cancer Metastasis and What PSMA Imaging is Teaching Us Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: Kenneth J. Pienta, MD, is the Donald S. Coffey Professor at the Brady Urological Institute at Jo...
|
- Details
- A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer. Diagnostic Molecular Imaging for Prostate Cancer in the United States - Andrei H Iagaru Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Chief, Division of Nuclear...
|
- Details
- A Step Towards Personalized Medicine: PSMA PET Imaging in Prostate Cancer Implications of PSMA PET Imaging for Prostate Cancer Presentation & Discussion - Oliver Sartor Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Presenter: A. Oliver Sartor, MD Professor of Medicine and Medical Director, Tulane Cancer Ce...
|
